Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

Stock Information for Cassava Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cassava Sciences Inc.

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.
Cassava Announces Closure of U.S. Department of Justice Investigation
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Cassava Announces Agreement to Settle Securities Class Action Litigation

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.